Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio22.06
Quick Ratio22.06
Price-To-Earnings
Trailing P/E Ratio-17.86
Forward P/E Ratio-14.42
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book7.11
Profitability
EPS (Most Recent Fiscal Year)($2.76)
Net Income$-117,020,000.00
Net MarginsN/A
Return on Equity-37.43%
Return on Assets-34.62%
Miscellaneous
Employees147
Outstanding Shares52,050,000
Market Cap$2.40 billion
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) posted its earnings results on Thursday, August, 2nd. The company reported ($0.78) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.09. During the same quarter last year, the business earned ($0.55) earnings per share. View Global Blood Therapeutics' Earnings History.
When is Global Blood Therapeutics' next earnings date?
What price target have analysts set for GBT?
14 Wall Street analysts have issued 1-year price objectives for Global Blood Therapeutics' stock. Their forecasts range from $61.00 to $125.00. On average, they anticipate Global Blood Therapeutics' share price to reach $82.5714 in the next year. This suggests a possible upside of 67.5% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.
What is the consensus analysts' recommendation for Global Blood Therapeutics?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (8/10/2018)
- 2. JPMorgan Chase & Co. analysts commented, "GBT reported 2Q results via press release (no conference call, as usual) that focused on lead program voxelotor in sickle cell disease. The print overall was uneventful as we await a regulatory update at some point in 2H18 on the potential for an accelerated approval filing. The other key event remaining this year is the presentation of detailed data from Part A of the Phase 3 HOPE trial anticipated at ASH in December." (8/5/2018)
- 3. Cantor Fitzgerald analysts commented, "We reaffirm our Overweight rating and $96 12-month price target for GBT. Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.7 billion ($88/share), and our estimate of YE18 cash of $424 million ($8/share)." (8/2/2018)
- 4. HC Wainwright analysts commented, "We continue to expect voxelotor in conjunction with HU to become the standard-of-care, especially in younger patients, which could make these patients asymptomatic much like SCD-trait subjects. Our Buy rating and price target of $125 is based on a DCF analysis, derived using a beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.4%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $$60K (increased from $75K and $50K) U.S." (7/27/2018)
- 5. Needham & Company LLC analysts commented, "Here we review our expectations for Part A of the HOPE trial which includes survey findings from 36 sickle cell disease (SCD) experts. We believe there is more than one path forward for voxelotor, but we think upside potential could vary significantly based on Part A findings. If reported Part A outcomes meet expectations as defined below, we think the stock could easily return to the $70 level (+60%) it was trading at in January." (4/26/2018)
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN) and Loxo Oncology (LOXO).
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Ted W. Love, President, Chief Executive Officer & Director
- Peter Radovich, Senior Vice President-Operations
- Jeffrey S. Farrow, Chief Financial Officer
- Jonathan Sorof, Senior Vice President-Medical & Regulatory affairs
- Jung E. Choi, Chief Business & Strategy Officer
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Has Global Blood Therapeutics been receiving favorable news coverage?
Headlines about GBT stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Global Blood Therapeutics earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Global Blood Therapeutics.
Who are Global Blood Therapeutics' major shareholders?
Global Blood Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.39%), Janus Henderson Group PLC (7.98%), BlackRock Inc. (7.96%), Orbimed Advisors LLC (0.86%), Nexthera Capital LP (0.78%) and Schwab Charles Investment Management Inc. (0.50%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.
Which institutional investors are selling Global Blood Therapeutics stock?
GBT stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, FMR LLC, Renaissance Technologies LLC, Columbus Circle Investors, BNP Paribas Arbitrage SA, Trexquant Investment LP, Alps Advisors Inc. and Dupont Capital Management Corp. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun and Peter Radovich. View Insider Buying and Selling for Global Blood Therapeutics.
Which institutional investors are buying Global Blood Therapeutics stock?
GBT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, grace capital, Nexthera Capital LP, Los Angeles Capital Management & Equity Research Inc., American Century Companies Inc., California Public Employees Retirement System and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy shares of Global Blood Therapeutics?
Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of GBT stock can currently be purchased for approximately $49.30.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.40 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
